Lv1
34 积分 2022-03-16 加入
Development of Dual-Receptor Lysosome-Targeting Chimeras for Protein Degradation
16小时前
已完结
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
12天前
已完结
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
21天前
已完结
Discovery of Potent and Highly Selective Interleukin-2-Inducible T-Cell Kinase Degraders with In Vivo Activity
1个月前
已完结
A first-in-class pulsatile FXR agonist for bile-acid-related liver diseases
1个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
2个月前
已完结
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
2个月前
已完结
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
2个月前
已完结
Endocytosis and intracellular trafficking of ErbBs
2个月前
已完结
Safety considerations for cereblon-recruiting targeted protein degraders
3个月前
已完结
皖公网安备34019202002308
